Transaction
Blue Corporate Finance advised AXA Private Equity, the leading European diversified private equity firm, on the acquisition of Riemser Arzneimittel AG, an internationally operating specialty pharmaceutical company. AXA Private Equity has acquired the shareholdings of Riemser’s founding Braun family and those of various minority stakeholders, including TVM Capital.
Deal rationale
With its global network, AXA Private Equity will be actively supporting the strategy of continued specialization and internationalization which has been pursued by Riemser’s management. The completion of the transaction remains subject to approval by the German competition authority.
Client
AXA Private Equity is a world leader in private equity, with assets of $28 billion managed or advised in Europe, North America and Asia. The company offers its investors a wide choice of funds covering the full range of asset classes: Funds of Funds (primary, early secondary and secondary), Direct Funds including Infrastructure, Small and Mid Market Enterprise Capital, Innovation & Growth, Co-Investment and Private Debt.
With offices in Paris, Frankfurt, New York, Singapore, Milan, London, Zurich, Vienna and Luxembourg AXA Private Equity is committed to supporting companies in their long term growth by providing access to its international network. AXA Private Equity sets great store by the regularity and quality of its reporting on the performance of its funds and the performance of the companies in its portfolio, as a service to its investors.
Target
Riemser Arzneimittel AG, headquartered in Greifswald, Germany, is a midsize specialty pharmaceutical company which markets its products in Germany and in 72 other countries. Riemser focuses principally on prescription-only human medicinal products in selected therapeutic markets with high medical need, in particular Oncology, Anti-Infectives, Dermatology and Dental.
Contact
Similar Transactions
